Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 98

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 98
---
    investigations,
    proceedings, or litigation that involve or affect us;

    ●
    the occurrence of
    any of the other risk factors included in this Report; and

    ●
    general market and
    economic conditions.

Our
Common Stock is currently listed on The NYSE American LLC (“NYSE American)”. NYSE American may delist our Common Stock
from trading, which could limit investors’ ability to make transactions in our securities and subject us to additional trading
restrictions.

Should
we fail to satisfy the continued listing requirements for remaining listed on NYSE American, such as the corporate governance
requirements or the minimum closing bid price requirement, NYSE American may take steps to delist our Common Stock. Such a delisting
would likely have a negative effect on the price of our Common Stock and would impair your ability to sell or purchase our Common
Stock when you wish to do so. In the event of a delisting, we would take actions to restore our compliance with NYSE American’s
listing requirements, but we can provide no assurance that any such action taken by us would allow our Common Stock to become
listed again, stabilize the market price or improve the liquidity of our Common Stock, prevent our Common Stock from dropping
below NYSE American’s minimum bid price requirement or prevent future non-compliance with such listing requirements.

If
we cannot maintain the listing of our Common Stock for trading on NYSE American, we could face significant material adverse consequences,
including:

    ●
    a limited availability
    of market quotations for our Common Stock;

    ●
    reduced liquidity
    for our Common Stock;

    ●
    a determination
    that our Common Stock is a “penny stock” which will require brokers trading in our Common Stock to adhere to more
    stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our Common
    Stock;

    ●
    a limited amount
    of news and analyst coverage; and

57 

    ●
    a decreased ability
    to issue additional Common Stock or obtain additional financing in the future.

We
could issue “blank check” preferred stock without stockholder approval with the effect of diluting then current stockholder
interests and impairing their voting rights; and provisions in our charter documents could discourage a takeover that stockholders
may consider favorable.

Our
articles of incorporation authorizes the issuance of up to 20,000,000 shares of “blank check” preferred stock with